摘要
目的探讨和分析肾康栓联合糖皮质激素及环磷酰胺治疗原发性肾病综合征患者的临床疗效。方法方便选取自2017年1月—2018年5月该院收治的76例患者,依据随机原则将患者划定为实验组与对照组(各38例),两组患者都采用降脂、子抗凝等疗法,对照组加入了糖皮质激素及环磷酰胺进行治疗。实验组在对照组基础上,还辅以肾康栓进行治疗,两组治疗周期均为8周,然后对比以上两组的总有效率,并检测CHOL(总胆固醇)、以及24 h尿蛋白、ALB(血清白蛋白)与TG (甘油三酯)等指标进行对比。结果在经过8周治疗之后,实验组患者的总有效率达到94.7%,明显优于对照组(81.6%),该两组的总有效率对比差异有统计学意义(χ2=5.73±7,P<0.05);实验组患者在治疗后的ALB(血清白蛋白)、CHOL(总胆固醇)、以及24 h尿蛋白与TG (甘油三酯)分别是(39.2±0.29) g/L、(3.59±0.25) mmol/L、(2.07±0.49) g/L、(1.43±0.37) mmol/L,且较前比变动幅度都明显优于对照组,该两组的上述项目变动幅度对比差异有统计学意义(t=5.107、5.862、6.334、5.947,P<0.05)。结论对原发性肾病综合征患者而言,在传统疗法的基础上,选择肾康栓配合糖皮质激素及环磷酰胺来实施治疗,能够获得理想的效果,可以在临床大力普及推广。
Objective To investigate and analyze the clinical efficacy of Shenkangshuan combined with glucocorticoid and cyclophosphamide in the treatment of patients with primary nephrotic syndrome.Methods 76 patients admitted from January 2017 to May 2018 were convenient enrolled.The patients were assigned to the experimental group and the control group (38 cases each) according to the random principle.Both groups of patients used lipid-lowering,anticoagulation,etc.therapy,the control group was added with glucocorticoids and cyclophosphamide for treatment.The experimental group was treated with Shenkang suppository on the basis of the control group.The treatment cycle was 8 weeks.Then the total effective rate of the above two groups was compared,and CHOL (total cholesterol) and 24 h urine protein and ALB were detected.(Serum albumin) was compared with indicators such as TG (triglyceride).Results After 8 weeks of treatment,the total effective rate of the experimental group was 94.7%,which was significantly better than that of the control group (81.6%).There was a significant difference in the total effective rate between the two groups (χ^2=5.737,P<0.05).There was statistical significance in the experimental group.After treatment,ALB (serum albumin),CHOL (total cholesterol),and 24 h urinary protein and TG (triglyceride) were (39.2±0.29) g/L,(3.59±0.25) mmol/L,(2.07±0.49) g/L,(1.43±0.37) mmol/L,and the change ratio of the previous ratio was significantly better than that of the control group,were statistically significant(t=5.107,5.862,6.334,5.947,P<0.05).Conclusion For patients with primary nephrotic syndrome,on the basis of traditional therapy,the choice of Shenkang suppository combined with glucocorticoids and cyclophosphamide for treatment can achieve the desired effect and can be widely promoted in clinical practice.
作者
魏笑天
WEI Xiao-tian(Department of Circulatory and Urology,Huadian People's Hospital,Huadian,Jilin Province,132400 China)
出处
《中外医疗》
2019年第2期107-109,共3页
China & Foreign Medical Treatment
关键词
肾康栓
糖皮质激素
肾病综合征
Shenkang suppository
Glucocorticoid
Nephrotic syndrome
